Thermo Fisher Scientific

Improved scanning and processing of stained multiplexed tissue samples with the Invitrogen™ EVOS™ S1000 Spatial Imaging System

Applications, challenges, and future directions of molecular testing for identifying targetable genetic alterations

The importance of timely genomic profiling in NSCLC: a synopsis of an Educational Symposium at European Lung Cancer Conference (ELCC) 2024

Towards a world where NGS-based companion diagnostics are available, in house, for every new cancer therapy and every patient

Towards a world where NGS-based companion diagnostics are available, in house, for every new cancer therapy and every patient

The ever-developing tale of companion diagnostic tests in precision oncology

How do we decide which NGS technology is the best for detecting fusion variants?

Lung cancer patients can’t always wait for treatment – so rapid in-house NGS can facilitate precision therapy fast

Size isn’t everything when it comes to next-generation sequencing. For one NHS consortium, using multiple panels is changing the game

How companion diagnostic tests are helping cancer patients find personalized answers – and treatments – fast

Explore the performance of Thermo Scientific™ triple quadrupole LC-MS systems for the analysis of clinically relevant compounds, including steroids.

Are you expected to deliver consistent, reliable results, faster?

Implementing LC-MS requires sufficient justification and commitment of resources but can have a very positive impact on clinical and business goals.

White Paper: Be Sure, Today and Tomorrow—LC-MS in Clinical Research.

With the ongoing development of precision oncology and more and more biomarkers entering routine clinical testing...

Development of a robust, reliable, and reproducible workflow solution for the analysis and quantitation of immunosuppressant drugs in blood.

The healthcare industry looks toward new solutions to provide better outcomes at lower costs.

Torbay Hospital is a leading screening centre for bowel cancer and a regional training centre for NHS consultants. The efficiency of Thermo Fisher™ Excelsior™ tissue processors helps the hospital keep up with the increased demand and meet targeted turnaround times

Experience the advantages of dried spot analysis without all the cumbersome manual steps.

Our family of liquid chromatography mass spectrometry instruments for in vitro diagnostics provides clinical labs with consistent reliable results.

Evaluation of the Oncomine Comprehensive Assay Plus for comprehensive genomic profiling including homologous recombination deficiency assessment.

In this webinar, two laboratories share their journey in addressing these challenges and their decision to implement the Oncomine Dx Express Test. Explore how this rapid and automated NGS assay has empowered these laboratories to analyze challenging samples, streamline workflows, and deliver timely, high-quality genomic profiling to enhance patient care.

In their retrospective study Integra Connect investigated how this behavior affects outcomes.

In this webinar, our speakers will discuss the benefits of CGP and how this technique is utilized in their lab.

The use of genomic profiling for myeloid samples has accelerated in recent years due in part to increasing annotation of disease-associated biomarkers.

Fusion based biomarkers are becoming more and more important in precision oncology clinical research.

Whilst NGS has been instrumental to precision oncology research progress, practical hurdles have still been hindering its broad implementation…………Not anymore.

With the emergence of a new class of targeted precision oncology therapies, NTRK fusions are increasingly becoming biomarkers that pathology laboratories can test for in FFPE tumor tissue.

The Pathologist and Thermo Fisher Scientific are giving you the opportunity to delve into tumour mutation burden.

This webinar, will discuss the benefits of next generation sequencing (NGS) for simultaneous testing of multiple biomarkers in non-small cell lung cancer.

Tumour-specific mutations in plasma can serve as biomarkers for tumour detection, monitoring tumour response to therapies, detecting residual disease, and enabling long-term follow-up.